RT Journal Article
T1 Macrolides: a novel risk factor for carbapenemase-producing Enterobacterales in intensive care units.
A1 Soria-Segarra, Carmen
A1 Soria-Segarra, Claudia
A1 Catagua-Gonzalez, Angel
A1 Apolo-Matamoros, Marcia
A1 Vega-Franco, Franklin
A1 Chung-Sang, Miguel
A1 Narvaez-Peñaloza, Cesar
A1 Quijano-Grunauer, Raquel
A1 Gutierrez-Fernandez, Jose
K1 Carbapenemase
K1 Enterobacterales
K1 ICU
K1 intensive care unit
K1 risk factors
AB Carbapenemase-producing Enterobacterales (CPE) have emerged as a substantial cause of morbi-mortality worldwide, with a prevalence of approximately 5% in areas with high endemicity. However, available data may not be representative of developing countries, such as Ecuador. In this study, the incidence of CPE in Ecuador and risk factors for infection/colonisation were evaluated. A prospective cohort study was performed from February to April 2016 in seven intensive-care units of Guayaquil, Ecuador. Samples were processed according to the Centers for Disease Control and Prevention laboratory protocol and the CHROMagar mSuper CARBA agar method. Resistance to carbapenems was defined according to Clinical and Laboratory Standards Institute breakpoints. A modified carbapenemase inactivation method was used to identify carbapenamase production phenotypically with molecular confirmation by multiplex polymerase chain reaction. In total, 640 patients were enrolled. The incidence of CPE was 36.4% (N = 233). A multivariate analysis indicated that several factors were associated with CPE acquisition, included a long intensive care unit stay (OR 1.05; 95% CI 1.03-1.08; p  Macrolide use was a risk factor for CPE acquisition. This association should be evaluated further, especially in developing countries.
YR 2020
FD 2020-11-02
LK http://hdl.handle.net/10668/17756
UL http://hdl.handle.net/10668/17756
LA en
NO Soria-Segarra C, Soria-Segarra C, Catagua-González A, Apolo-Matamoros M, Vega-Franco F, Chung-Sang M, et al. Macrolides: a novel risk factor for carbapenemase-producing Enterobacterales in intensive care units. J Infect Dev Ctries. 2021 Apr 30;15(4):584-589.
DS RISalud
RD Apr 12, 2025